Teleflex (NYSE: TFX) stock surged 5.46% intraday on Thursday, as investors cheered stronger-than-expected adjusted earnings and a significant boost to the company's full-year profit guidance, even as the medical device maker trimmed its revenue forecast.

The company reported second-quarter adjusted earnings of $1.76 per share, handily beating the FactSet consensus estimate of $1.28 by 37.5%. Revenue of $570.3 million also topped analyst expectations of $559.6 million, driven by solid performance in its Vascular and Surgical businesses. While GAAP revenue growth was lifted by the acquisition of Biotronik's Vascular Intervention business, the integration is taking longer than expected, prompting management to modestly lower its full-year revenue outlook to a range of $2.26 billion to $2.28 billion.

However, the market focused on the brighter side of the report: Teleflex raised its 2026 adjusted diluted EPS guidance to $6.90–$7.20, well above the prior range of $6.25–$6.55 and the FactSet consensus of $6.67. The upward revision reflects the benefit of share repurchases—including the $250 million in buybacks completed during the quarter and a newly announced $250 million accelerated share repurchase program—as well as the repayment of the Term Loan A-2. The combination of a strong earnings beat and a sharply higher profit outlook fueled the stock's rally.